A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

16000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in Hubei at the end of 2022

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Changes of Optical Quality During the Peak of the Covid-19 Pandemic

NCT05882383

Corneal Wavefront Aberration SARS-CoV-2

COMPLETED

Eye Detection to Identify Novel Coronavirus Infection

NCT04907981

Covid19

COMPLETED

Clinical Features and Visual Prognosis of Infectious Endophthalmitis

NCT06755177

Endophthalmitis

COMPLETED

Retinal and Choroidal Microvascular Parameters in School-age Children in a COVID-19 Infection Pandemic Peak in China

NCT05952466

COVID-19 Pandemic

COMPLETED

Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness

NCT04910282

Covid19 Eye Diseases

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During late 2022 COVID-19 pandemic ocular discomforts were common in people with mild systemic symptoms, but most resolve on their own without any treatment. The disease spectrum of ophthalmology outpatient clinics is affected by the COVID-19 pandemic. In our study, we observed that the incidence of keratitis and acute angle-closure glaucoma in Phase A was significantly higher than that in Phase B and C.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Ocular Surface Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

the pandemic period (Phase A)

NOT

Intervention Type OTHER

NOT

the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 ).

the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).

NOT

Intervention Type OTHER

NOT

the prevention and control periods (Phase C: December 7, 2021 to January 6, 2022).

the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).

NOT

Intervention Type OTHER

NOT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOT

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. 2022.12.7 to 2023.2.6 People surveyed by wechat Questionnaire Star 2. 2021.12.7 to 2022.1.6 and 2022.11.7 to 2023.1.6 Patients who received ophthalmology treatment in Zhongnan Hospital of Wuhan University and Qichun People's Hospital

Exclusion Criteria

* 1\. currently hospitalized patients. 2. severe patients. 3. Incomplete information. 4. cannot be contacted by telephone. 5. Refuse questionnaire survey. 6.The electronic medical record information is incomplete. 7. Those who do not go to the ophthalmic clinic after registration. 8.severe patients. 9. Cannot be contacted by phone.

Eligible Sex

ALL

Accepts Healthy Volunteers

No